Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.04
TMO's Cash-to-Debt is ranked lower than
96% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. TMO: 0.04 )
Ranked among companies with meaningful Cash-to-Debt only.
TMO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.39 Max: N/A
Current: 0.04
Equity-to-Asset 0.47
TMO's Equity-to-Asset is ranked lower than
72% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. TMO: 0.47 )
Ranked among companies with meaningful Equity-to-Asset only.
TMO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.5 Max: 0.75
Current: 0.47
0.31
0.75
Interest Coverage 5.12
TMO's Interest Coverage is ranked lower than
77% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.16 vs. TMO: 5.12 )
Ranked among companies with meaningful Interest Coverage only.
TMO' s Interest Coverage Range Over the Past 10 Years
Min: 5.12  Med: 6.56 Max: 14.93
Current: 5.12
5.12
14.93
Piotroski F-Score: 8
Altman Z-Score: 2.76
Beneish M-Score: -2.47
WACC vs ROIC
7.31%
7.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 13.62
TMO's Operating Margin % is ranked higher than
77% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. TMO: 13.62 )
Ranked among companies with meaningful Operating Margin % only.
TMO' s Operating Margin % Range Over the Past 10 Years
Min: 10  Med: 11.79 Max: 14.82
Current: 13.62
10
14.82
Net Margin % 11.58
TMO's Net Margin % is ranked higher than
83% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. TMO: 11.58 )
Ranked among companies with meaningful Net Margin % only.
TMO' s Net Margin % Range Over the Past 10 Years
Min: 7.81  Med: 9.67 Max: 11.64
Current: 11.58
7.81
11.64
ROE % 10.13
TMO's ROE % is ranked higher than
67% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. TMO: 10.13 )
Ranked among companies with meaningful ROE % only.
TMO' s ROE % Range Over the Past 10 Years
Min: 5.36  Med: 7.8 Max: 10.13
Current: 10.13
5.36
10.13
ROA % 4.82
TMO's ROA % is ranked higher than
68% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. TMO: 4.82 )
Ranked among companies with meaningful ROA % only.
TMO' s ROA % Range Over the Past 10 Years
Min: 3.58  Med: 4.68 Max: 5.52
Current: 4.82
3.58
5.52
ROC (Joel Greenblatt) % 48.58
TMO's ROC (Joel Greenblatt) % is ranked higher than
79% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. TMO: 48.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TMO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 37.47  Med: 43.01 Max: 62.95
Current: 48.58
37.47
62.95
3-Year Revenue Growth Rate 8.70
TMO's 3-Year Revenue Growth Rate is ranked higher than
58% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. TMO: 8.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TMO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -19.8  Med: 8.7 Max: 24.4
Current: 8.7
-19.8
24.4
3-Year EBITDA Growth Rate 14.90
TMO's 3-Year EBITDA Growth Rate is ranked higher than
70% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. TMO: 14.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TMO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -39.2  Med: 14.9 Max: 36.2
Current: 14.9
-39.2
36.2
3-Year EPS without NRI Growth Rate 13.40
TMO's 3-Year EPS without NRI Growth Rate is ranked higher than
65% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. TMO: 13.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TMO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -43.5  Med: 14 Max: 74.6
Current: 13.4
-43.5
74.6
GuruFocus has detected 6 Warning Signs with Thermo Fisher Scientific Inc $TMO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TMO's 30-Y Financials

Financials (Next Earnings Date: 2017-07-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

TMO Guru Trades in Q3 2016

Ken Fisher 1,482 sh (New)
Pioneer Investments 2,645,237 sh (+1.98%)
Eaton Vance Worldwide Health Sciences Fund 231,352 sh (+64.08%)
First Eagle Investment 200 sh (unchged)
Joel Greenblatt Sold Out
John Rogers 526,143 sh (-1.94%)
PRIMECAP Management 5,204,870 sh (-2.94%)
Diamond Hill Capital 551,677 sh (-3.90%)
David Dreman 9,343 sh (-4.77%)
Vanguard Health Care Fund 4,097,300 sh (-5.06%)
Mairs and Power 1,683 sh (-5.77%)
Larry Robbins 2,686,316 sh (-6.02%)
First Pacific Advisors 1,676,150 sh (-6.30%)
Steven Romick 1,306,510 sh (-7.72%)
Ray Dalio 10,600 sh (-14.97%)
Mario Gabelli 27,345 sh (-15.98%)
Signature Select Canadian Fund 72,350 sh (-16.07%)
Paul Tudor Jones 3,000 sh (-16.67%)
Manning & Napier Advisors, Inc 413,541 sh (-34.50%)
Dodge & Cox 67,602 sh (-87.16%)
» More
Q4 2016

TMO Guru Trades in Q4 2016

Wallace Weitz 132,160 sh (New)
Steven Cohen 183,552 sh (New)
Jim Simons 813,644 sh (New)
Caxton Associates 40,000 sh (New)
Ray Dalio 28,700 sh (+170.75%)
Larry Robbins 3,659,734 sh (+36.24%)
Diamond Hill Capital 647,502 sh (+17.37%)
Ken Fisher 1,707 sh (+15.18%)
Mario Gabelli 29,220 sh (+6.86%)
PRIMECAP Management 5,304,730 sh (+1.92%)
Manning & Napier Advisors, Inc 415,211 sh (+0.40%)
First Eagle Investment 200 sh (unchged)
Mairs and Power 1,683 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 231,352 sh (unchged)
David Dreman 8,862 sh (-5.15%)
Vanguard Health Care Fund 3,884,800 sh (-5.19%)
John Rogers 483,526 sh (-8.10%)
First Pacific Advisors 1,460,100 sh (-12.89%)
Steven Romick 1,134,900 sh (-13.13%)
Paul Tudor Jones 2,500 sh (-16.67%)
Pioneer Investments 2,185,073 sh (-17.40%)
Dodge & Cox 50,002 sh (-26.03%)
» More
Q1 2017

TMO Guru Trades in Q1 2017

Joel Greenblatt 10,891 sh (New)
David Tepper 160,000 sh (New)
Prem Watsa 1,344 sh (New)
Jeremy Grantham 1,800 sh (New)
Paul Tudor Jones 8,545 sh (+241.80%)
Jim Simons 1,373,044 sh (+68.75%)
Ken Fisher 2,602 sh (+52.43%)
Wallace Weitz 135,545 sh (+2.56%)
Pioneer Investments 2,219,085 sh (+1.56%)
Diamond Hill Capital 648,596 sh (+0.17%)
First Eagle Investment 200 sh (unchged)
Mairs and Power 1,683 sh (unchged)
Steven Romick 1,134,900 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 231,352 sh (unchged)
Steven Cohen Sold Out
Caxton Associates Sold Out
PRIMECAP Management 5,271,490 sh (-0.63%)
First Pacific Advisors 1,441,070 sh (-1.30%)
Mario Gabelli 28,825 sh (-1.35%)
Dodge & Cox 48,287 sh (-3.43%)
John Rogers 463,398 sh (-4.16%)
Vanguard Health Care Fund 3,721,300 sh (-4.21%)
Larry Robbins 2,972,060 sh (-18.79%)
Manning & Napier Advisors, Inc 327,503 sh (-21.12%)
Signature Select Canadian Fund 44,850 sh (-38.01%)
Ray Dalio 8,844 sh (-69.18%)
David Dreman 37 sh (-99.58%)
» More
Q2 2017

TMO Guru Trades in Q2 2017

Diamond Hill Capital 714,693 sh (+10.19%)
Steven Romick 1,134,900 sh (unchged)
Manning & Napier Advisors, Inc 271,710 sh (-17.04%)
Ken Fisher 1,284 sh (-50.65%)
» More
» Details

Insider Trades

Latest Guru Trades with TMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}